UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017947
Receipt number R000020721
Scientific Title Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab
Date of disclosure of the study information 2015/06/21
Last modified on 2015/06/17 15:45:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab

Acronym

Efficacy and serum IL-6 in RA treated with tocilizumab

Scientific Title

Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab

Scientific Title:Acronym

Efficacy and serum IL-6 in RA treated with tocilizumab

Region

Japan


Condition

Condition

Rheumatoid arthritis

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine efficacy and serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Remission rate at 24 weeks.
Change of serum IL-6 levels at 24 weeks and 52 weeks

Key secondary outcomes

Remission rate at 12 weeks and 52 weeks


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with RA who met the 1987 revised criteria of ACR or the 2010 ACR/EULAR classification criteria.
Patients with active RA who had been treated with at least one biologics.

Key exclusion criteria

Patients who corresponds to a contraindication of tocilizumab

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshifumi Tada

Organization

Saga University hospital

Division name

Department of Rheumatology

Zip code


Address

5-1-1 Nabeshima, Saga

TEL

0952-34-2367

Email

taday@cc.saga-u.ac.p


Public contact

Name of contact person

1st name
Middle name
Last name Yoshifumi Tada

Organization

Saga University

Division name

Department of Rheumatology

Zip code


Address

5-1-1 Nabeshima, Saga

TEL

0952-34-2367

Homepage URL


Email

taday@cc.saga-u.ac.jp


Sponsor or person

Institute

Department of Rheumatology, Saga University

Institute

Department

Personal name



Funding Source

Organization

Saga University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2013 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Undetermined


Management information

Registered date

2015 Year 06 Month 17 Day

Last modified on

2015 Year 06 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020721


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name